newsfilter
← Latest News
GlobeNewswire·

Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

- Reported combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial demonstrating Nana-val's substantial antitumor activity